Compare Quest Diagnostics Inc (DGX) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Weibo Corp — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Weibo Corp trades at $6.54 (market cap $1.56B). The key difference: Quest Diagnostics Inc is far larger — about 16.3× Weibo Corp's market cap, and Weibo Corp pays the higher dividend (9.47%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Weibo Corp for 102 Days on average.
| DGX | WB | |
|---|---|---|
Market Cap | $25.48B | $1.56B |
Volume | 941,866 | 812,503 |
Sector | Health | Media |
52-Week High | $247.45 | $11.61 |
52-Week Low | $173.49 | $6.33 |
Typical Hold Time | 56 Days | 102 Days |
Enterprise Value | $31.23B | $786.69M |
Dividend Yield | 1.49% | 9.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
Weibo (WB) trades at $6.44, down 0.62% with a bearish technical outlook. The stock shows attractive valuation metrics with P/E of 5.32 and P/B of 0.4, while maintaining strong profitability with 73.36% gross margins. Recent Q2 2026 earnings beat expectations with $0.38 EPS, though Q4 2025 and Q1 2026 missed. Cash flow trends show volatility, with 2024 net cash flow negative $694 million but improving to positive $408 million in 2025. Analyst sentiment is mixed with 40.91% buy ratings amid concerns about user growth stagnation.
WB presents as a deep-value opportunity with compelling valuation multiples but faces headwinds from declining user metrics and advertising revenue challenges. The risk-reward profile favors patient investors willing to tolerate near-term volatility for potential multiple expansion, though competitive pressures and regulatory uncertainties in China's social media landscape require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
